On 3 February 2026, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act was enacted, enabling Medicare coverage for multi-cancer early detection (MCED) tests. This legislation coincides with new results from key clinical trials and has important implications for payers and policymakers, given the lack of FDA approval of any MCED test or evidence that population screening with such tests reduces cancer-related or all-cause mortality.
Wan, J. C.
M., Sasieni, P. & Rosenfeld, N.
Promises and pitfalls of multi-cancer early detection using liquid biopsy tests. Nat.
Rev. Clin.
Oncol. 22 , 566–580 (2025).
Kadakia, K. T., Dhruva, S.
S., Ross, J. S.
& Rathi, V. K.
Automatic Medicare coverage for new medical technologies — here we go again. N.
Engl. J.
Med. 394 , 213–215 (2026).
McCartney, M. & Cohen, D.
Galleri promises to detect multiple cancers-but new evidence casts doubt on this much hyped blood test. BMJ 386 , q1706 (2024).
Fleming, N. Cancer blood tests are everywhere.
Do they really work? Nature 651 , 22–24 (2026).
Nature Reviews Clinical Oncology published a clinical update in Oncology on 14 May 2026.
The item focuses on Clinical implementation of multi-cancer early detection tests: can we find a path forward?.
Review the original article for the full source wording and details.